Impact of Desmopressin on Clinical Outcomes in Patients with Spontaneous Antiplatelet-Associated Intracerebral Hemorrhage Undergoing Neurosurgical Intervention: An Observational Multicenter Study

What Was Tested

This observational study looks at Vasopressin and Desmopressin.

Desmopressin acetate (DDAVP) is commonly employed as a management strategy.

This multicenter study aims to compare the functional and safety outcomes in patients with or without preoperative DDAVP administration after spontaneous antiplatelet-associated ICH.

Who Took Part

According to the abstract, 2023, patients were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

From January 2016 to November 2023, the researchers enrolled patients with spontaneous ICH who were under antiplatelet therapy and needed neurosurgical interventions in the emergency departments.

Patients were excluded for traumatic brain injury, ICH from subarachnoid hemorrhage, arteriovenous malformation, intracranial tumors, coagulopathies, and anticoagulant use.

How the Study Was Run

The researchers set it up as a multicenter study.

Running at several centres spread the Vasopressin study over different clinics and patient groups.

The primary outcome was the modified Rankin Scale (mRS) 4-6 at discharge.

Secondary endpoints included safety outcomes and in-hospital and follow-up outcomes.

What Was Measured

PubMed files the paper under topics including Cerebral Hemorrhage, Deamino Arginine Vasopressin, Platelet Aggregation Inhibitors, Neurosurgical Procedures and Hemostatics.

Author keywords: Antiplatelet agent, desmopressin acetate, intracerebral hemorrhages, neurosurgery and treatment outcome.

What This Means in Plain Language

The paper is a multicenter study of Vasopressin and Desmopressin in 2023, patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Shock (Augusta, Ga.)), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.